Treatment with Benlysta (belimumab) induces meaningful and long-lasting reductions in systemic lupus erythematosus (SLE) disease activity, helping a significant proportion of patients achieve durable remission or a status of low disease activity, a study in a real-world Italian population shows. Patients diagnosed in the prior two years, with…
Rheumatologists, researchers, and patients have joined forces on a global scale to better understand how COVID-19 affects people with rheumatic diseases, including those with systemic lupus erythematosus (SLE). The COVID-19 Global Rheumatology Alliance registry, which had more than 100 cases within one week of launching, “represents…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on the FDA’s fast track program if it can treat serious conditions and fill an unmet clinical need, either because no…
RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune diseases like systemic lupus erythematosus (SLE) now in a pivotal clinical trial. The funding will also support the China-based company’s early stage treatment discovery platform, help expand its manufacturing…
Panniculitis — a group of conditions that causes painful bumps to appear under the skin — is a rare manifestation of childhood-onset systemic lupus erythematosus (cSLE) that occurs mainly in the first three years of disease, and seems to be an indicator of less severe systemic lupus, a study found.
Omalizumab — a treatment already approved for allergic asthma and chronic hives — is well-tolerated and reduces disease activity in patients with systemic lupus erythematosus (SLE), a Phase 1b clinical trial shows. Findings were published in the study, “Safety and Tolerability of Omalizumab, A Randomized Clinical…
The U.S. Food and Drug Administration has granted fast track status to baricitinib for the treatment of systemic lupus erythematosus (SLE) patients, the treatment’s developers, Eli Lilly and Incyte, announced. Fast track designation is intended to speed the therapy’s development and review for lupus patients, enabling more frequent communication with…
Zostavax, a live attenuated herpes zoster vaccine, is well-tolerated and causes an antibody response in patients with systemic lupus erythematosus (SLE), who have a significant risk of herpes zoster infection and reactivation, a trial shows. The research, “Safety and Immune Response of a Live Attenuated Herpes…
Systemic lupus erythematosus (SLE) patients with highly active disease responded well to treatment with atacicept at 150 mg each week — especially those on continuous treatment for about one year, results from a Phase 2b study and its long-term extension show. The findings were revealed at the American College…
Ustekinumab as an add-on to standard of care was seen to significantly increase the number of systemic lupus erythematosus (SLE) patients with a reduction in disease activity compared to standard of care alone, results from a Phase 2 trial show. Patients were also less likely to experience a disease flare…